Apellis Pharmaceuticals Inc (APLS)
47.46
-0.03
(-0.06%)
USD |
NASDAQ |
May 03, 16:00
46.01
-1.45
(-3.06%)
After-Hours: 20:00
Apellis Pharmaceuticals Profit Margin (Quarterly): -60.51% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -60.51% |
| September 30, 2023 | -127.0% |
| June 30, 2023 | -128.5% |
| March 31, 2023 | -396.4% |
| December 31, 2022 | -732.4% |
| September 30, 2022 | -867.2% |
| June 30, 2022 | -955.6% |
| Date | Value |
|---|---|
| March 31, 2022 | -966.1% |
| December 31, 2021 | -245.4% |
| September 30, 2021 | -3.46K% |
| June 30, 2021 | -35.18K% |
| March 31, 2021 | |
| December 31, 2020 | 31.31% |
| September 30, 2020 | -21.01K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-35.18K%
Minimum
Jun 2021
31.31%
Maximum
Dec 2020
-4.93K%
Average
-732.4%
Median
Dec 2022
Profit Margin (Quarterly) Benchmarks
| Blueprint Medicines Corp | -154.1% |
| Sarepta Therapeutics Inc | 8.74% |
| Alnylam Pharmaceuticals Inc | -13.34% |
| Ionis Pharmaceuticals Inc | -2.85% |
| Madrigal Pharmaceuticals Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -195.2% |
| Return on Assets | -62.02% |
| Return on Invested Capital | -145.3% |
| Gross Profit Margin (Quarterly) | 86.40% |
| Operating Margin (Quarterly) | -57.74% |
| Return on Net Operating Assets | -184.7% |